No­var­tis scraps key PD-1 sub­mis­sion, while tout­ing 'sig­nif­i­cant bolt-on M&A fire­pow­er'

No­var­tis is no longer sub­mit­ting tislelizum­ab for ap­proval in the US as a monother­a­py for non-small cell lung can­cer — mark­ing the sec­ond ma­jor set­back in the last week on its high-dol­lar quest to bring a Chi­na-de­vel­oped PD-1 check­point to the US.

On the com­pa­ny’s Q2 call, CEO Vas Narasimhan re­vealed that No­var­tis and its part­ners at BeiGene have no plans at this time to file for the monother­a­py in­di­ca­tion af­ter re­ceiv­ing “FDA feed­back.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER